FDA outlines strategy to further increase resiliency of US infant formula market

The agency remains committed to improving the infant formula supply

The US Food and Drug Administration (FDA) has released a national strategy outlining actions the agency will take immediately to help ensure one of the nation’s most vulnerable populations continue to have access to safe, nutritious infant formula and to increase resiliency of the US infant formula market and supply.

The strategy will focus on ensuring that the industry is aware of requirements to develop and implement redundancy risk management plans. These plans are intended to help industry identify risks to the supply chains of infant formula and medical foods and to develop mitigation plans against potential disruptions that could impact production.

It will continue to enhance inspections of infant formula manufacturers, by expanding and improving infant formula training for investigators; and expediting review of premarket submissions for new infant formula products to mitigate or prevent shortages.

The focus will also be on engaging with US government partners who play a role in mitigating other factors that may influence the infant formula supply, such as tariffs and market concentration, to sustain the safe, continuous production of infant formula; and engaging with the US Department of Agriculture to support efforts to build resiliency within its Special Supplemental Nutrition Programme for Women, Infants, and Children (WIC).

Image credit- shutterstock